At the 2026 SCOPE Summit, Boehringer Ingelheim’s Wouter Daniels argued that true patient centricity begins with site centricity. Daniels shared how Boehringer’s engagement efforts have accelerated studies by months and saved millions — proof that patient focus delivers measurable business and operational value.
- Safe And Sustainable DCTs and Hybrid Trials (Part 2)
- Rethinking Clinical Trials In Rare Neurodegenerative Diseases: Lessons From Alterity's MSA Trial
- Clinical Trials Need Fewer Barriers And More Humans
- Forget More Clinical Tech, We Need More Adoption
- Breaking Through Tumor Defenses With Next-Generation Cell Therapy
- Reprogramming The Tumor Microenvironment: Bringing A Metabolic Checkpoint Therapy Into The Clinic
- Joe Dustin: Sites Are Driving Clinical Tech Evolution
GUEST COLUMNISTS
-
![Dietitian holding diet plan-GettyImages-1425188874]( "The Problem With Excluding Children From GLP-1 Trials In The U.S.")
The Problem With Excluding Children From GLP-1 Trials In The U.S.In the U.S., roughly 15 million children are obese. But many are excluded from GLP-1 research. Obesity expert Evan Nadler, MD, explains why that's problematic.
-
![Various Pills on White Stripes of American Flag-GettyImages-172849908]( "U.S. Pharma Tariffs And MFN In 2026: Manufacturing And Procurement Impact")
U.S. Pharma Tariffs And MFN In 2026: Manufacturing And Procurement ImpactBeroe Inc.'s Mathini Ilancheran discusses the 2025 U.S. pharma tariff framework and translates it into actionable procurement and outsourcing responses.
-
![Woman using smartwatch-GettyImages-2248203064]( "How AI-Enabled Personal Health Tools Are Reshaping Clinical Trial Workflows")
How AI-Enabled Personal Health Tools Are Reshaping Clinical Trial WorkflowsLearn how AI-enabled personal health technologies are impacting key aspects of trial operations while also exploring operational challenges that clinical operations leaders must manage in this AI-driven era.
-
![Female nurse working at hospital-GettyImages-1333203074]( "4 Steps For Representative Enrollment In Rare Disease Trials")
4 Steps For Representative Enrollment In Rare Disease TrialsDiscover the D.A.T.A. method and its utility in enrolling diverse representative patient populations in rare disease clinical trials.
-
![Smart Chips, AI-GettyImages-1326193256]( "When AI Meets Accounting: AI Costs And Intangible Asset Treatment For Sponsors And CROs")
When AI Meets Accounting: AI Costs And Intangible Asset Treatment For Sponsors And CROsLearn how to account for AI-related costs under evolving U.S. Generally Accepted Accounting Principles (GAAP).
-
![FDA]( "FDA Issues Final Guidance On Clinical Trial Participation: What You Need To Do Now")
FDA Issues Final Guidance On Clinical Trial Participation: What You Need To Do NowOn December 15, 2025, the FDA finalized its guidance Enhancing Participation in Clinical Trials, formally updating expectations for enrollment and trial design. Here's what you can do now.
-
![AI, Holographic AI chip interface with European Union flag-GettyImages-2244741422]( "How To Operationalize AI-Enabled eTMF Systems Under The EU AI Act (Part 2)")
How To Operationalize AI-Enabled eTMF Systems Under The EU AI Act (Part 2)Learn how to comply with the EU AI Act when AI is used in GCP-critical eTMF contexts in part two of this series by Donatella Ballerini.
-
![European Union AI Act hologram-GettyImages-2244742120]( "How AI-Enabled eTMF Systems Are Impacted By The EU AI Act (Part 1)")
How AI-Enabled eTMF Systems Are Impacted By The EU AI Act (Part 1)Learn how the EU AI Act reshapes the regulatory treatment of AI-enabled eTMF systems with consultant Donatella Ballerini.
CLINICAL TRIAL WHITE PAPERS
-
![GettyImages-1163267030 treadmill weight loss]( "Looking Beyond Weight Loss In The Obesity Pandemic: What's Next?")
Looking Beyond Weight Loss In The Obesity Pandemic: What's Next?Here, we analyze the current landscape of obesity management, underscoring the critical need for comprehensive approaches that prioritize overall well-being beyond simple weight reduction.
-
Participant Payments: Navigating Modern Studies12/18/2024
To address the challenges of disbursing clinical trial participant payments globally, sponsors need region-specific payment solutions that navigate local laws and banking systems.
-
Patient-Reported Outcome In Oncology Clinical Trials4/17/2025
As cancer therapies grow more complex and personalized, patient-reported outcomes (PROs) have emerged as a vital component of oncology research and care.
-
Paper Vs ePRO: Clinical Data Collection Methods7/16/2024
Patient-reported outcomes (PROs) assess patients' health without clinician interpretation. Traditional paper methods often result in missing data and quality issues, while electronic solutions enhance data accuracy and completeness.
-
Guide To Pharmaceutical CAPA And Quality Management3/14/2025
CAPA management is vital for quality systems, especially in pharmaceuticals. Examine how issues are identified, corrected, and prevented to safeguard health and uphold regulatory compliance.
-
Tracking Functional Capacity To Advance Neuromuscular Disease Research2/6/2026
This presentation introduces a dual-endpoint approach to monitoring neuromuscular disease progression through two high-centile digital measures.
CLINICAL TRIAL APP NOTES & CASE STUDIES
-
GSK And Medable Discuss The Next Phase Of DCTs3/10/2025
GSK and Medable share the value of embedding DCTs into strategic goals to enhance trial accessibility, diversity, and efficiency.
-
Launching A Unified Global Sales Team In 90 Days11/7/2025
A global CRO united 300+ sales and executive leaders across five continents for a dynamic, space-themed meeting that strengthened culture, deepened product understanding, and inspired alignment toward annual growth goals.
-
DTx Company Leverages Real-World Evidence Platform In Registry Study8/19/2024
Discover how Castor’s eClinical system enabled a groundbreaking study in behavioral disorder treatment to collect Real-World Evidence (RWE) to support product research and claims.
-
How Syneos Health Tackles Protocol Complexities1/7/2025
Explore solutions employed by Syneos Health, a global contract research organization, to optimize Phase IIV clinical trials, particularly under a complex adaptive trial protocol.
-
Top 10 Global Pharma Company Dramatically Improves Site Payments In Drive To Become Sponsor Of Choice10/30/2024
See how a pharma company reduced investigator payment cycle time by 55% while decreasing their own administrative burden by 90% in this metrics-rich case study.
-
How To Seamlessly Integrate NetSuite With Power BI8/12/2024
Unlock the power of your NetSuite data with seamless integration to Power BI. Learn how to automate data refresh, gain real-time insights, and make informed business decisions.
NEWSLETTER ARCHIVE
- 02.25.26 -- 4 Steps To Make A Business Case For Digital Endpoints
- 02.25.26 -- STREAM Edition: CRL Transparency Comes With Real Trade-Secret Risks
- 02.24.26 -- When AI Meets Accounting: AI Costs And Intangible Asset Treatment For Sponsors And CROs
- 02.23.26 -- The U.S. Trial Advantage Is Eroding
- 02.21.26 -- The Case For Research-Naive PIs
RECRUITMENT AND DIVERSITY
This section includes some helpful resources regarding patient recruitment and diversity in clinical trials, including this link to the FDA's guidance on diversity action plans.
-
![Dietitian holding diet plan-GettyImages-1425188874]( "The Problem With Excluding Children From GLP-1 Trials In The U.S.")
In the U.S., roughly 15 million children are obese. But many are excluded from GLP-1 research. Obesity expert Evan Nadler, MD, explains why that's problematic.
-
![Woman using smartwatch-GettyImages-2248203064]( "How AI-Enabled Personal Health Tools Are Reshaping Clinical Trial Workflows")
Learn how AI-enabled personal health technologies are impacting key aspects of trial operations while also exploring operational challenges that clinical operations leaders must manage in this AI-driven era.
-
![Female nurse working at hospital-GettyImages-1333203074]( "4 Steps For Representative Enrollment In Rare Disease Trials")
Discover the D.A.T.A. method and its utility in enrolling diverse representative patient populations in rare disease clinical trials.
FOCUS ON PATIENTS
-
![Father playing with child-GettyImages-1567083882]( "Time Is Lives: How Collaboration And Urgency Are Rewriting The Future Of Rare Disease")
The inflection point has arrived, says Rob Freishtat, MD, MPH. Understand how collaboration will rewrite how we think of rare disease clinical research.
-
![Dietitian holding diet plan-GettyImages-1425188874]( "The Problem With Excluding Children From GLP-1 Trials In The U.S.")
In the U.S., roughly 15 million children are obese. But many are excluded from GLP-1 research. Obesity expert Evan Nadler, MD, explains why that's problematic.
-
![Woman using smartwatch-GettyImages-2248203064]( "How AI-Enabled Personal Health Tools Are Reshaping Clinical Trial Workflows")
Learn how AI-enabled personal health technologies are impacting key aspects of trial operations while also exploring operational challenges that clinical operations leaders must manage in this AI-driven era.
